2-(p-Methylbenzyl)-cyclopentanon | 54158-56-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(p-Methylbenzyl)-cyclopentanon
• 英文别名: 2-[(4-Methylphenyl)methyl]cyclopentan-1-one
• CAS: 54158-56-4
• 化学式: C₁₃H₁₆O
• 分子量: 188.269
• InChiKey: AMWHISPUMUVDDD-UHFFFAOYSA-N

物化性质

• 沸点：
  303.8±11.0 °C(Predicted)
• 密度：
  1.047±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(p-Methylbenzyl)-cyclopentanon 在 (S)-(CF₃)₃-t-BuPHOX 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三乙胺 、 四丁基二氟三苯硅酸铵 、 sodium iodide 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 54.0h， 生成 (S)-2-allyl-2-(4-methylbenzyl)cyclopentanone 、 (R)-2-allyl-2-(4-methylbenzyl)cyclopentanone
  参考文献：
  名称：

  Palladium-Catalyzed Enantioselective Decarboxylative Allylic Alkylation of Cyclopentanones

  摘要：

  The first general method for the enantioselective construction of all-carbon quaternary centers on cyclopentanones by enantioselective palladium-catalyzed decarboxylative allylic alkylation is described. Employing the electronically modified (S)-(p-CF3)(3)-t-BuPHOX ligand, alpha-quaternary cyclopentanones were isolated in yields up to >99% with ee's up to 94%. Additionally, in order to facilitate large-scale application of this method, a low catalyst loading protocol was employed, using as little as 0.15 mol % Pd, furnishing the product without any loss in ee.

  DOI：

  10.1021/acs.orglett.5b02376
• 作为产物：
  描述：

  (4-甲基苯基)甲醇 、 环戊酮 在 C₅₁H₃₉As₂N₃O₂RuS 、 sodium hydroxide 作用下， 以 甲苯 为溶剂， 反应 8.0h， 以80%的产率得到2-(p-Methylbenzyl)-cyclopentanon
  参考文献：
  名称：

  方便的（II）配合物的合成和结构表征：通过氢自动转移，用伯醇与酮进行α-烷基化的高效催化剂

  摘要：

  摘要为了开发新的配合物，新的Ru（II）配合物（1-3）由[Ru（SAL-HBT）（CO）（AsPh3）2]，[Ru（VAN） -HBT）（CO）（AsPh3）2]和[Ru（NAP-HBT）（CO）Cl（AsPh3）2] [SAL-HBT =（水杨基（（2-（苯并噻唑-2基）肼基）甲基苯酚））， VAN-HBT = 2-（（（2-（苯并噻唑-2-基）肼基）甲基）-6甲氧基苯酚）和NAP-HBT =萘基-2-（（2-（苯并噻唑-2-基）肼基）甲基苯酚）合成。通过令人满意的元素分析，各种光谱技术（IR，（1H，13C）NMR）以及质谱法确定了它们的身份。钌（II）离子具有扭曲的八面体几何形状的六配位体。在配合物1和2中，配体通过形成N 1 N供体5元和N 2 O供体6元螯合环而以双阴离子三齿形式配位。然而，在配合物3中，配体通过形成N 1 N供体五元环以单阴离子二齿形式配位。新的钌（II）羰基

  DOI：

  10.1016/j.ica.2020.119887

文献信息

• Simple Epoxide Analogs of Trichothecans
  作者：Neal C. Corbin、Phillip Fraher、James D. McChesney

  DOI：10.1002/jps.2600681210

  日期：1979.12

  To define clearly the epoxide grouping role in trichothecan biological activity, a series of hindered epoxides was prepared. They possessed alpha, alpha'-substitution reminiscent of the epoxide environment of the natural products. None of these analogs demonstrated biological activities similar to the natural toxins.

  为了清楚地定义在天花胶生物活性中的环氧基分组作用，制备了一系列受阻的环氧化物。它们具有让人想起天然产物的环氧化物环境的α，α'-取代。这些类似物均未显示出与天然毒素相似的生物学活性。
• PESTICIDALLY ACTIVE KETONE AND OXIME DERIVATIVES
  申请人：Zambach Werner

  公开号：US20080200525A1

  公开（公告）日：2008-08-21

  Compounds of formula wherein A 0 , A 1 and A 2 are each independently of the others a bond or a C 1 -C 6 alkylene bridge; A 3 is a C 1 -C 6 alkylene bridge which is unsubstituted or substituted by from one to six identical or different substituents selected from halogen and C 3 -C 8 cycloalkyl; Y is, for example, O, S, SO or SO 2 ; M is O or NOR 6 , X 1 and X 2 are each independently of the other fluorine, chlorine or bromine; R 1 , R 2 and R 3 are, for example, H, halogen, OH, SH, CN, nitro, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkylcarbonyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl or C 2 -C 6 alkynyl; Q is, for example, O, S, SO or SO 2 ; W is, for example, O, S, SO, SO 2 , —C(═O)—O— or —O—C(═O)—; T is, for example, a bond, O, S, SO, SO 2 , —C(═O)—O— or —O—C(═O)—; D is CH or N; R 4 is, for example, H, halogen, OH, SH, CN, nitro, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl; R 5 is, for example, C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl or —N(R 7 ) 2 ; R 7 is H, C 1 -C 6 alkyl, C 1 -C 3 haloalkyl, C 1 -C 6 alkylcarbonyl, C 1 -C 3 haloalkylcarbonyl, C 1 -C 6 alkoxycarbonyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkylcarbonyl or formyl; k is 0, 1, 2, 3 or 4; m is 1 or 2; and q is 0, 1 or 2; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds and agrochemically acceptable salts thereof, and a process for the preparation of those compositions and their use, to plant propagation material treated with those compositions, and a method of controlling pests.

  该公式的化合物中，A0、A1和A2分别独立地是键或C1-C6烷基桥；A3是C1-C6烷基桥，未取代或取代为1-6个相同或不同的卤素和C3-C8环烷基的取代基；Y是例如O、S、SO或SO2；M是O或NOR6；X1和X2各自独立地是氟、氯或溴；R1、R2和R3是例如H、卤素、OH、SH、CN、硝基、C1-C6烷基、C1-C6卤代烷基、C1-C6烷基羰基、C2-C6烯基、C2-C6卤代烯基或C2-C6炔基；Q是例如O、S、SO或SO2；W是例如O、S、SO、SO2、-C（═O）-O-或-O-C（═O）-；T是例如键、O、S、SO、SO2、-C（═O）-O-或-O-C（═O）-；D是CH或N；R4是例如H、卤素、OH、SH、CN、硝基、C1-C6烷基或C1-C6卤代烷基；R5是例如C1-C12烷基、C3-C8环烷基或-N（R7）2；R7是H、C1-C6烷基、C1-C3卤代烷基、C1-C6烷基羰基、C1-C3卤代烷基羰基、C1-C6烷氧羰基、C3-C8环烷基、C3-C8环烷基羰基或甲酰基；k是0、1、2、3或4；m是1或2；q是0、1或2；如适用，其可能的E/Z异构体、E/Z异构体混合物和/或互变异构体，在自由形式或盐形式中，以及制备这些化合物的方法、选择这些化合物为活性成分的杀虫剂组合物和农用化学品可接受的盐的使用、制备这些组合物的方法和使用这些组合物处理植物繁殖材料、以及控制害虫的方法。
• HIGH PENETRATION COMPOSITIONS AND USES THEREOF
  申请人：Yu Chongxi

  公开号：US20090238763A1

  公开（公告）日：2009-09-24

  The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

  本发明涉及新型高渗透性组合物或高渗透性前药（HPP）的组成和用途，特别是用于非甾体抗炎药（NSAIAs）的HPP，其能够高效地穿过生物屏障。这里的HPP能够在穿过生物屏障后转化为父活性药物或药物代谢物，从而可以治疗与父药物或代谢物相关的疾病。此外，由于能够穿过生物屏障，这里的HPP能够到达父药物可能无法进入或无法在目标区域产生足够浓度的区域，从而提供新的治疗方法。这里的HPP可以通过各种给药途径给予受试者。例如，由于其穿透生物屏障的能力，HPP可以在局部给药到疾病作用部位并以高浓度存在，从而避免系统性给药的需要。另一个例子是，这里的HPP可以被系统性地给药到生物体内，并以更快的速率进入循环系统。
• NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：EARL Richard A.

  公开号：US20100093671A1

  公开（公告）日：2010-04-15

  The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

  该发明描述了新型亚硝酰化非甾体抗炎药（NSAIDs）及其药学上可接受的盐，并且描述了至少包含一种亚硝酰化NSAID和可选的至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，刺激内源性一氧化氮的合成，提高内源性内皮源性松弛因子的水平或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID和至少一种化合物的新型组合物，该化合物捐赠、转移或释放一氧化氮，提高内源性内皮源性松弛因子的水平，刺激内源性一氧化氮的合成或是一氧化氮合酶的底物，并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID，可选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防使用非甾体抗炎化合物导致的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的方法。
• Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use
  申请人：Earl Richard

  公开号：US20110098253A1

  公开（公告）日：2011-04-28

  The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.

  该发明还提供了治疗炎症、疼痛和发热的方法；治疗胃肠道疾病的方法；促进伤口愈合的方法；治疗和/或预防非甾体类抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法；治疗炎症性疾病状态和/或疾病的方法；以及治疗和/或预防眼科疾病和/或疾病的新组合物的给药方法，该组合物包括至少一种硝化的非甾体类抗炎药，以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂。